Destiny Pharma. Share News (DEST)

Destiny Pharma on track for commercial agreement for NTCD-M3 drug

(Alliance News) - Destiny Pharma PLC on Thursday said partnering negotiations for its NTCD-M3 clinical programme are nearing finalisation.

Destiny Pharma eyes potential billion dollar returns from Nasal asset

(Alliance News) - Destiny Pharma PLC on Wednesday said it has finalised development plans for phase three testing of its late-stage clinical asset, XF-73 Nasal, which aims to prevent post-surgical staphylococcal infections.

Destiny Pharma finalises plans for next study of its lead asset

(Sharecast News) - Biotechnology company Destiny Pharma has finalised plans for phase-three studies of its late-stage clinical asset 'XF-73 Nasal', it announced on Wednesday.

Destiny Pharma starts new drug study for its skin infection treatment

(Alliance News) - Destiny Pharma PLC on Tuesday said it had started a safety study to enable its XF-73 treatment to be labelled as an Investigational New Drug.

Destiny Pharma starts new safety study of dermal formulation

(Sharecast News) - Biotechnology developer Destiny Pharma announced the start of an investigational new drug (IND)-enabling safety study with its novel 'XF-73 Dermal' formulation.

Destiny Pharma loss widens, pins hope on late stage clinical assets

(Alliance News) - Destiny Pharma PLC on Thursday reported a widened interim loss, as it progresses two key clinical assets.

Destiny Pharma gets positive EMA feedback for gut bacteria treatment

(Alliance News) - Destiny Pharma PLC on Wednesday announced that it had received positive feedback from the European Medicine Agency on its NTCD-M3 phase 3 development plans.

Destiny Pharma receives 'positive feedback' from EMA on NTCD-M3

(Sharecast News) - Clinical stage biotechnology company Destiny Pharma has received "positive feedback" from the European Medicine Agency regarding the proposed Phase III development programme of its new antibiotic treatment.

UK earnings, trading statements calendar - next 7 days

TRADING UPDATES: De La Rue cancels contract; Apollon buys in Jamaica

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

TRADING UPDATES: Capital backs outlook; Northcoders trades well

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Destiny Pharma awarded Cystic Fibrosis Foundation project

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma has received an award from the Cystic Fibrosis Foundation, it announced on Tuesday.

IN BRIEF: Destiny Pharma receives undisclosed grant for MRSA study

Destiny Pharma PLC - Brighton-based clinical-stage biotechnology company - Receives undisclosed grant from Maryland-based non profit Cystic Fibrosis Foundation for a study on its drug candidate XF-73 on disease-causing bacteria MRSA.

IN BRIEF: Destiny Pharma XF-73 shown to enhance activity of two drugs

Destiny Pharma PLC - Brighton-based clinical-stage biotechnology company - New data on its XF-73 drug show that it can boost the effectiveness of current standard of care antibiotics when used in combinational therapy. The new in-vitro data stemmed from experiments by studies at the School of Dentistry, Cardiff University, for the potential for XF-based drugs to enhance the effectiveness of key antibacterial treatments. When combined with polymyxin B, a last resort antibacterial drug used to treat life-threatening lung bacterial infections, XF-73 enhanced polymyxin B potency against Pseudomonas aeruginosa, a top priority WHO bacterial pathogen, by 4-fold, the research found.

IN BRIEF: Destiny Pharma begins research on XF-73 for oral mucositis

Destiny Pharma PLC - Brighton-based clinical-stage biotechnology company - Starts new research programme in the US on oral mucositis, an inflammation of the mouth that is a common side effect of chemotherapy and radiotherapy. Firm tests its experimental drug candidate XF-73 as potential preventive medicine to ease suffering from oral mucositis. Explains that XF-73 has shown unique antimicrobial properties in phase 2 clinical trials.